Insurance Payments for Bone Marrow Transplantation in Metastatic Breast Cancer

To the Editor: Autologous bone marrow transplantation has been a controversial treatment for metastatic breast cancer. Proponents of the procedure have pointed to studies indicating an increase in disease-free survival with this approach, whereas others have suggested that the improved survival has...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 342; no. 15; pp. 1138 - 1139
Main Author van Amerongen, Derek
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 13.04.2000
Subjects
Bone Marrow Transplantation - economics
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Humans
Insurance, Health, Reimbursement - statistics & numerical data
Insurance, Health, Reimbursement - trends
Neoplasm Metastasis - therapy
Ohio
Transplantation, Autologous
Ohio
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Autologous bone marrow transplantation has been a controversial treatment for metastatic breast cancer. Proponents of the procedure have pointed to studies indicating an increase in disease-free survival with this approach, whereas others have suggested that the improved survival has been due to patient selection. 1 From 1996 through 1998, the number of requests for autologous bone marrow transplantation for metastatic breast cancer received by Anthem Blue Cross increased from 64 per year to 83 per year. Two important events occurred in May 1999: the company expanded the indications for autologous bone marrow transplantation for metastatic breast cancer to . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM200004133421515